We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Correction: J Exp Clin Cancer Res 42:44 (2023)
Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 3; specifically in Fig. 3C and D. The image for the NCI-N87 cell line in Fig. 3C (row 1) was mistakenly included. Consequently, the corresponding statistical analysis for NCI-N87 in Fig. 3D also needs to be corrected.
The corrected figure is given below. The correction does not have any effect on the results or conclusions of the paper.
The original article [1] has been corrected.
Incorrect Figure 3.
Cellular effects of the combination of ABE and JQ1 on in vitro GC cell models. A Representative synergy models of ABE and JQ1 across GC cell lines. B Bar plot of the average and maximum of synergy score among 13 GC cell lines. score > 10 indicates synergy. score < -10 indicates antagonism. C Crystal violet staining of colonies from six representative cell lines during 2 weeks with the indicated treatment of DMSO, ABE (100nM), JQ1(100nM), and ABE (100nM) + JQ1 (nM). D Quantification of the colonies area using imageJ software. The data are presented as the mean ± SEM of three replicates. E Representative Cell cycle plots of different GC cell lines treated with DMSO, ABE (1000nM), JQ1(500nM), or ABE (1000nM) + JQ1(500nM) for 48 h as examined by flow cytometry analyses. F Representative histograms of the ratio of G1, S, and G2 phase of GC cell lines with different treatments
Correct Figure 3.
Cellular effects of the combination of ABE and JQ1 on in vitro GC cell models. A Representative synergy models of ABE and JQ1 across GC cell lines. B Bar plot of the average and maximum of synergy score among 13 GC cell lines. score > 10 indicates synergy. score < -10 indicates antagonism. C Crystal violet staining of colonies from six representative cell lines during 2 weeks with the indicated treatment of DMSO, ABE (100nM), JQ1(100nM), and ABE (100nM) + JQ1 (nM). D Quantification of the colonies area using imageJ software. The data are presented as the mean ± SEM of three replicates. E Representative Cell cycle plots of different GC cell lines treated with DMSO, ABE (1000nM), JQ1(500nM), or ABE (1000nM) + JQ1(500nM) for 48 h as examined by flow cytometry analyses. F Representative histograms of the ratio of G1, S, and G2 phase of GC cell lines with different treatments
Reference
Feng M, Xu H, Zhou W, et al. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023;42:44. https://doi.org/10.1186/s13046-023-02615-2.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s13046-023-02615-2.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Feng, M., Xu, H., Zhou, W. et al. Correction: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res 43, 199 (2024). https://doi.org/10.1186/s13046-024-03126-4
Published:
DOI: https://doi.org/10.1186/s13046-024-03126-4